The Effect of Comorbidities on Glycemic Control Among Colombian Adults With Diabetes Mellitus: a Longitudinal Approach With Real-world Data

Manuel Urina-Jassir  
Fundación del Caribe para la Investigación Biomédica

Lina Johana Herrera-Parra  
Cuenta de Alto Costo, Fondo Colombiano de Enfermedades de Alto Costo

Juliana Alexandra Hernández Vargas  
Cuenta de Alto Costo, Fondo Colombiano de Enfermedades de Alto Costo

Ana María Valbuena-García  
Cuenta de Alto Costo, Fondo Colombiano de Enfermedades de Alto Costo

Lizbeth Acuña-Merchán  
Cuenta de Alto Costo, Fondo Colombiano de Enfermedades de Alto Costo

Miguel Urina-Triana (murina1@unisimonbolivar.edu.co)  
Facultad de Ciencias de la Salud, Universidad Simón Bolívar, Barranquilla

Research Article

Keywords: Glycated Hemoglobin A1c, Diabetes Mellitus, Comorbidity, Hypertension, Chronic Kidney Disease, Obesity

DOI: https://doi.org/10.21203/rs.3.rs-156202/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Achieving an optimal glycemic control has been described to reduce the incidence of diabetes mellitus (DM) related complications. The association between comorbidities and glycemic control remains unclear. Our aim is to evaluate the effect of comorbidities on glycemic control in people with DM.

**Methods:** A retrospective longitudinal study on data from the National Registry of Chronic Kidney Disease from 2014 to 2019 in Colombia. The outcome was poor glycemic control (PGC = HbA1c ≥ 7.0%). The association between each comorbidity (hypertension (HTN), chronic kidney disease (CKD) or obesity) and PGC was evaluated through multivariate mixed effects logistic regression models. The measures of effect were odds ratios (OR) and their 95% confidence intervals (CI). We also evaluated statistical interaction between each comorbidity and ethnicity.

**Results:** From 969,531 people at baseline, 85% had at least one comorbidity; they were older and mostly female. In people with DM and CKD, the odds of having a PGC were 78% (OR: 1.78, CI 95%: 1.55-2.05) higher than those without CKD. Same pattern was observed in obese for whom the odds were 52% (OR: 1.52, CI 95%: 1.31-1.75) higher than in non-obese. Non-significant association was found between HTN and PGC. The association of interest was statistically modified by ethnicity (afro descendant).

**Conclusions:** Prevalence of comorbidities was high in adults with DM. Patients with concomitant CKD or obesity had significantly higher odds of having a PGC.

1. Background

Diabetes Mellitus (DM) prevalence is increasing worldwide[1]. The International Diabetes Federation estimated that 9.3% (463 million people) of the global adult population had DM in 2019; with an unsettling projection of 10.2% (578 million people) and 10.9% (700 million people) for 2030 and 2045, respectively [1]. The same phenomenon was true for the South and Central American region; with a prevalence up to 8.5% (31.6 million people) and a prediction up to 9.9% (49.1 million people) in 2045 [1]. The aforementioned region includes Colombia, a country where DM prevalence ranges from 1.8–11.2% depending on the source of data [2]. This is alarming given the effects DM has on morbidity and the sustainability of health systems [3].

Achieving an optimal glycemic control has been described to decrease the incidence of DM related complications[4–7]. As for microvascular complications, in a recent meta-analysis a more rigorous control was found to reduce the relative risk by 20% and 13% for kidney and eye outcomes, respectively [5]. On the other hand, an effect on macrovascular complications was also described with a reduction in cardiovascular events when intensive glycemic control is employed [6, 7]. In spite of this, only few patients reach the established target; a meta-analysis described that approximately 36% of patients in randomized control trials and 34% in cross-sectional studies achieved the hemoglobin A1c (HbA1c) target (≤ 7.0% or < 7.0%, respectively) [8].

Different sociodemographic and clinical factors appear to be associated with glycemic control. Regarding age and gender, female and younger patients were more commonly associated with poor control[9]. Taking into account race and ethnicity, studies have demonstrated significant differences between ethnic groups in achieving glycemic target[10, 11]. An additional determinant of inadequate glycemic control is a longer time since the diagnosis of DM[9, 12].
Comorbid conditions, mainly hypertension (HTN), obesity, hyperlipidemia, chronic kidney disease (CKD) and cardiovascular disease, are common in patients with DM [13]. Studies evaluating the relationship between the presence of comorbidities and glycemic control have showed contradictory findings depending on the analysis. When the total number of comorbidities was used, studies have found no relationship [14] or an inverse relationship[15] between comorbidities and HbA1c. Research using comorbidity scores also established no relationship with HbA1c levels [16]. Whereas in a study evaluating specific comorbidities, subjects with HTN and dyslipidemia were found to have lower odds of achieving glycemic target while no significant association was observed with CKD[17]. Lastly, DM patients with overweight or obesity were more commonly associated with poor glycemic levels [18].

There are not many studies in Latin America evaluating the different factors, especially comorbidities, that can influence on glycemic control. Therefore, our aim was to assess the longitudinal association between the presence of comorbidities (HTN, CKD and obesity) and glycemic control among Colombian adults diagnosed with DM from 2014 to 2019.

2. Methods

2.1 Data sources

We conducted a retrospective longitudinal analysis on data of people diagnosed with DM who were reported by health insurers and providers to the National Registry of Chronic Kidney Disease (NRCKD) from July 1st, 2013 to June 30th, 2019 in Colombia. The NRCKD is managed by the High-Cost Diseases Fund (“Cuenta de Alto Costo” in Spanish). It has been operating since 2008 by a resolution from the Ministry of Health of Colombia[19]. The NRCKD aims to evaluate the burden of CKD and its most common precursors (HTN and DM) as well as the effective access to health services related to prevention, diagnosis and control across the country.

The NRCKD is an administrative and passive registry with a national scope because approximately 98% of the population is affiliated to the national healthcare system [20], and their insurers are required to report patients with HTN, DM or CKD to the registry [19]. A unique identification number is assigned to each individual protecting their personal information and allowing future follow up. When a new case enters the NRCKD, a complete registration is done; for old cases, data are updated every year.

The NRCKD undergoes a data auditing process to ensure the veracity of the information. The first step involves the use of an algorithm to identify mistakes in the reporting process. After this, an experienced team compares the reported information with health clinical records by a well-established data monitoring process in a representative stratified sample of cases with HTN and/or DM, with or without CKD. In case of any inconsistency is identified, the real data on clinical records is captured.

2.2 Eligibility of participants

A total of 1,081,863 people aged 18 years or more, diagnosed with DM were reported to the NRCKD from 2014 to 2019. 112,332 were excluded because they had no information available on the measurement of HbA1c. Indeed, 969,531 people met the inclusion criteria and were analyzed. Figure 1 shows the eligibility flow of the population studied.
2.3 Exposure and outcome variables

The presence of comorbidities (HTN, CKD, obesity), reported by health insurers to the NRCKD was considered as the exposure of interest. HTN diagnosis was defined as its presence or absence, based on clinical judgement according to international guidelines. CKD was categorized as follows: yes/no/undetermined/not studied for CKD during the reporting period. People classified as undetermined were those with early kidney impairment that require evidence of functional or structural injury for more than three months. Lastly, obesity was determined using the World Health Organization definition (body mass index \[BMI\] ≥ 30 kg/m²) [21]. Exhaustiveness and accuracy of exposures were verified in clinical records by a well-established data monitoring process.

A poor glycemic control (PGC) was the dependent variable. It was defined by the measurement of HbA1c, reported during the last six months of each follow up period. PGC was treated as a dichotomous variable for each point in time using the cutoff of HbA1c ≥ 7.0%, according to the standard defined by the American Diabetes Association [22].

2.4 Covariates

Demographic information included age, gender, health insurance (third payer, state insurance, special insurance, exception insurance or uninsured), and region of residence following the Administrative Department for National Statistics (“Departamento Administrativo Nacional de Estadística” in Spanish) classification (Bogotá D.C., Central, Eastern, Pacific, Caribbean and Amazonian) [23]. Ethnicity was self-reported and classified in indigenous, afro descendant and other (white, mestizo, gypsy or not classified). In respect of clinical data, age at diagnosis of DM and comorbidities were included. Reported information on weight (kg) and height (meters) was used to calculate BMI (kg/m²). Otherwise, glomerular filtration rate (GFR) was estimated using the CKD-EPI method and expressed as mL/min/1.73m² [24]. On the other hand, CKD stages were defined based on the GFR as follows: 1: GFR >90 with clinical evidence of kidney damage; 2: GFR: 60-90 with clinical evidence of kidney damage; 3: GFR: 30-60, 4: GFR 15-30, 5: GFR: <15 [25]. Lastly, DM duration was calculated using the date of last contact (last HbA1C test) and the date of diagnosis and informed in years.

2.5 Statistical analysis

Baseline demographic and clinical characteristics of the cohort are presented as means or medians and their standard deviation (SD) or interquartile range (IQR), according to their distribution, evaluated by statistical and graphical methods. Otherwise, qualitative data is informed as absolute values (proportions). Baseline characteristics were compared across comorbidities (HTN, CKD and obesity) by using a X² test for categorical data and Wilcoxon test was used for numeric variables. We also calculated absolute standardized differences (ASD) between groups of comorbidities to avoid limitations of hypothesis tests taking into account the effect of the sample size. In the case of continuous variables with skewed distribution, rank statistics were used instead the mean [26]. ASD >10% were considered significant.

Furthermore, the trend of variation on HbA1c levels during the follow-up for patients with different baseline comorbidity profiles was evaluated by estimating generalized linear mixed models assuming random intercepts for each participant. An interaction term between HbA1c levels and time was included to take into account variations over time. From each model, the predicted Hb1Ac values were plotted over time according to each comorbidity.
The association of interest was estimated using a mixed effects logistic regression model with aleatory intercept, which modelates the odds of PGC for each point in time, taking into account the effect of repeated measures and considering the parameters related to the intercept differentially between each participant, but with a constant slope. The final model for each comorbidity was adjusted by age, gender, ethnicity, health insurance, duration of diabetes. In case of HTN and CKD we also included the BMI (time variant) as a confounder in the final models. Effect measures were the odds ratios and their 95% confidence intervals. Furthermore, the interaction between each comorbidity and intermediate variables such us ethnicity was explored by the inclusion of a multiplicative term in the final models. $p$ values <0.05 (two-tailed) were considered statistically significant, except for the effect modification model ($p$-value <0.20). Trend and association models were estimated using a case complete approach including people with 6-year HbA1c measurement (n= 107,091). All statistical analyses were performed in Stata version 13 (StataCorp LP, College Station, Texas, USA) and graphs were created in R version 4.0.2.

### 2.6 Sensitivity analysis

We performed sensitivity analysis including a BMI $\geq 25$ kg/m$^2$ instead of $\geq 30$ kg/m$^2$ as the exposition to verify the consistency of the association obtained in the main model. Furthermore, we evaluated the association in people with CKD by using a different cut off to define the outcome (HbA1c $\geq 8.0\%$).

### 3. Results

#### 3.1 Demographic and clinical characteristics at baseline

969,531 people were analyzed. Mean age at baseline was 61.4 years (SD 13.2), 58.1% were female and 75.1% had third payer insurance. Most people (29.5%) lived in the Central region, followed by Bogotá D.C. (20.3%). Around 96.0% were self-recognized as "other" ethnicity and 3.5% were afro descendant. Mean age at DM diagnosis was 59.2 years (SD 13.0) and median of DM duration was 2.76 years (IQR 1.0–6.0). Prevalence of HTN, CKD and obesity were 71.5%, 30.6% and 35.2%, respectively. Majority of the people with CKD were classified in stage 2 (44.0%) and 3 (28.8%).

Table 1 shows a characterization by comorbidities. Only 14.9% did not have an associated comorbidity at baseline. Prevalence of comorbidities was higher in women. People with comorbidities were older, except for those with obesity. Age at DM diagnosis was also higher in people with comorbidities. ASD were significant for DM duration in all groups, except for the obese. When comparing the prevalence of obesity by comorbidities, it was also higher in people with HTN and CKD.

#### 3.2 Trends of longitudinal variation on HbA1c by comorbidities

After a 6-year follow up, people with DM and HTN or CKD had a better glycemic control (lower HbA1c levels) than those with obesity. In both DM subjects with HTN or CKD, HbA1c levels were lower in those who had the condition. These findings were contrary to the obese/not obese subjects, where we found higher HbA1c levels when obesity was present. A higher gap in the HbA1c levels between the presence or not of comorbidities was observed in people with DM and HTN/no HTN than in the other groups. When estimating the longitudinal variation on HbA1c when changing the cut-off from BMI $\geq 30$ kg/m$^2$ to $25$ kg/m$^2$, the trend was opposite to the observed in obese, with a better glycemic control in those with a BMI $\geq 25$ kg/m$^2$. 

Page 5/12
3.3 Longitudinal association between comorbidities and glycemic control

The mean number of HbA1c measurements was 3.18 (SD 1.7). Only 11.0% of the patients had 6-year HbA1c measurements and were included in the final models. Global prevalence of PGC was 52.7% (95% CI: 52.6 to 52.8). When analyzing the effect of comorbidities on PGC (HbA1c ≥ 7.0), we observed a non-significant direct association between HTN and a PGC in all models, except for the multivariable model that included BMI as a random variable which showed a non-significant inverse association (Table 2). Nevertheless, CKD and obesity were significant and directly associated with PGC in all models. In subjects with DM and CKD, the odds of having a PGC were 78.0% (OR: 1.78, CI 95%: 1.55–2.05) higher than those without CKD. We also observed a strong direct association among people with DM and obesity, in whom the odds were 52.0% (OR: 1.52, CI 95%: 1.31–1.75) higher than in non-obese. (Table 2)

Table 2
Multivariate-adjusted odds of poor glycemic control by comorbidities in Colombian adults with diabetes mellitus, 2014–2019

| Model                              | Hypertension | Chronic kidney disease | Obesity                           |
|------------------------------------|--------------|------------------------|-----------------------------------|
|                                    | OR           | 95% CI                 | p-value  | OR           | 95% CI       | p-value  | OR           | 95% CI       | p-value  |
| Age adjusted                       | 1.08         | 0.91–1.28              | 0.36     | 1.76         | 1.54–2.02    | < 0.01   | 1.49         | 1.30–1.71    | < 0.01   |
| Multivariable 1 (Fixed BMI)        | 1.08         | 0.91–1.28              | 0.36     | 1.75         | 1.53–2.00    | < 0.01   | 1.46         | 1.27–1.68    | < 0.01   |
| Multivariable 1 (Time variant BMI) | 0.98         | 0.83–1.16              | 0.84     | 1.87         | 1.64–2.14    | < 0.01   | NA           | NA           | NA       |
| Multivariable 2 (Fixed BMI)        | 1.04         | 0.87–1.24              | 0.66     | 1.67         | 1.45–1.93    | < 0.01   | 1.52         | 1.31–1.75    | < 0.01   |
| Multivariable 2 (Time variant BMI) | 0.94         | 0.78–1.13              | 0.53     | 1.78         | 1.55–2.05    | < 0.01   | NA           | NA           | NA       |

1 Adjusted for age (continuous), gender (men vs women) and body mass index (continuous and fixed).

2 Adjusted for age (continuous), gender (men vs women) and body mass index (continuous and time variant).

3 Adjusted for age (continuous), gender (men vs women), body mass index (continuous and fixed), ethnicity (indigenous or afro descendant vs. other), health insurance (state insurance or uninsured vs. third payer) and diabetes duration (continuous).

4 Adjusted for age (continuous), gender (men vs women), body mass index (continuous and time variant), ethnicity (indigenous or afro descendant vs. other), health insurance (state insurance or uninsured vs. third payer) and diabetes duration (continuous).

Abbreviations: OR: odds ratio, CI: confidence interval, BMI: body mass index
When evaluating the interaction between comorbidity and ethnicity, we only identified a statistically significant interaction between each comorbidity and afro-descendants (all \( p \)-values were < 0.01). Predictive probabilities of having a PGC were significantly lower in afro-descendant with HTN compared with afro descendant without HTN. Otherwise, an inverse effect was found in afro descendant with CKD who had a significantly higher probability of a PGC. Afro descendant with obesity, had a lower probability of a PGC, following the same pattern observed with HTN, however, the effect was not significant (Fig. 2).

### 3.4 Sensitivity analysis

The associations of interest were consistent with the main models (Additional File 1: Table S1). When analyzing the effect of a BMI \( \geq 25 \) kg/m\(^2\) on the outcome, we observed the same direction and significance but a lower magnitude in respect of the final model including obesity (OR: 1.26, CI 95%: 1.06–1.49). Similarly, direction and statistical significance remained, although the magnitude decreased when the cut-off point of HbA1c was slightly higher to define the PGC (OR: 1.30, CI 95%: 1.11–1.52).

### 4. Discussion

This study evaluated the effect that common diabetes associated comorbidities (CKD, HTN and obesity) have on glycemic control among a Colombian adult population with DM. Longitudinal, non-adjusted trend of HbA1c over time showed a better glycemic control in people with HTN, CKD and non-obese. However, when estimating multivariate models, an inverse effect was found, and people with diabetes and CKD or obesity had significantly higher odds of having a PGC compared to those without the comorbidities. Whereas a non-significant association was found between HTN and a PGC.

Our study showed that CKD was associated with 78% increased odds of having a PGC. Taking into account that a less strict goal may be recommended in patients with DM and advanced comorbid diseases [22, 27], we conducted a sensitivity analysis with a less strict threshold (PGC as HbA1c \( \geq 8.0\% \)). Even with this flexible target, the findings were consistent. Patients with DM and CKD had an increase likelihood of PGC when compared to those without CKD even with a less stringent goal. In addition to this, when evaluating the interaction between CKD and ethnicity, we found that afro descendants with DM and CKD also had an increased probability of PGC compared to those without CKD. Our overall findings are consistent to those found by De Cosmo et al. where CKD (defined as low GFR, high albuminuria or both) was associated with a lower probability of achieving the HbA1c target established in a large Italian population with DM [28]. However, others have reported that people with DM and CKD had lower odds of having suboptimal glycemic control [29].

It is important to note that despite some limitations that are beyond the scope of this article, HbA1c is still considered the standard for glycemic follow-up in patients with CKD [27, 30] thus giving relevance to our results. These findings should increase the concern of clinicians taking care of patients with kidney dysfunction given the consequences of a PGC have on DM patients with CKD. A meta-analysis of patients with DM treated with hemodialysis described an increased risk of mortality in people with HbA1c \( \geq 8.5\% \) when compared to lower levels (6.5–7.4\%) [31]. Also, Kuo et al. observed that HbA1c levels > 9\% were associated with an increased risk of end stage renal disease and mortality in patients with diabetes and CKD stages 3–4 [32].

Similar to the CKD effect on PGC, we observed that obese people were 52\% more likely to have a PGC than those without obesity. When a lower threshold was used (\( \geq 25 \) kg/m\(^2\)), the results followed a similar trend, but
magnitude decreased to 26%. Together, these results indicate that an elevated BMI increases the risk of PGC in patients with DM. Similar conclusions have been described in previous studies [29, 33]. A cross sectional study in Iranian population with diabetes found an association between obesity and poor glycemic control [33]. Furthermore, Bae et al. describe an increased probability of suboptimal glycemic control when overweight or obesity was present in patients with DM in the USA [29]. Nevertheless, Chetoui et al. did not find an association between overweight/obesity and poor glycemic control in a Moroccan population with type 2 DM [12]. In a therapeutically point of view, Gummesson et al. stated that weight reduction in overweight and obese patients with type 2 DM is consistently followed by a reduction on HbA1c levels [34].

Some authors have described the presence of HTN as a predictor of poor glycemic control [17, 33]. However, we did not find a significant association between HTN and PGC. Our results are consistent with those of Badedi et al. describing no association between HTN and HbA1c [35]. Though, this was different when evaluating the interaction between ethnicity and HTN. We found that afro descendant with DM and HTN had a lower predictive probability of PGC than those without HTN; other ethnicities did not have a significant association. Various authors have described an association between ethnicity and glycemic control [10, 11]. A cross sectional study in the USA, found that non-Hispanic blacks and Mexican Americans when compared to non-Hispanic whites had lower odds of adequate glycemic control [11]. Additionally, the same study described that the proportion of patients with three comorbidities (HTN, Hyperlipidemia and obesity) achieving glycemic control (HbA1c < 7.0%) changed according to their ethnicity: 22.8%, 11.4% and 0% of non-Hispanic whites, non-Hispanic blacks and Mexican Americans, respectively [11].

This study has important strengths. First of all, this report reflects a national scope since data come from the largest registry of people with CKD in the country. By including people with different comorbidities, our results are representative of the Colombian population with DM who receive services within the framework of the health system. Furthermore, a longitudinal approach was used and the effect of repeated measures during the follow up was considered in the final models. This differs from the commonly used cross sectional analysis in studies evaluating factors influencing glycemic control. On the other hand, the use of HbA1c has been well described to evaluate long term glycemic control and because we only studied people with a new DM diagnosis, changes in glycemic control over time are meaningful for decision making process at a clinical and organizational level.

Some limitations should be considered when interpreting our findings. There is a clear effect of medication and non-pharmacological treatment on prospective glycemic control. Nonetheless, we were unable to adjust for treatment because these data were unavailable so residual confusion cannot be ruled out. Moreover, the NRCKD is a passive registry and reporting process is performed by health care insurers; this can lead to underreporting and despite it is minimal, it must be declared. Linked to the above, data on variables are likely subjected to measurement error. Nevertheless, its impact was limited through the data monitoring process. In any case this error would be non-differential and effect estimations tend to the null.

5. Conclusions

In this adult population with DM, patients with concomitant CKD or obesity had an increased likelihood of PGC. This supports the importance of weight reduction in diabetes treatment; as well as the increased surveillance and treatment needed in the CKD population. Our findings are based on data from real-world clinical practice thus they should be helpful for public health entities in decision making process. The strategies should be directed in
improving access to healthcare, surveillance and treatment in these patients given the detrimental effects of PGC. Whether the presence of HTN modifies the probability of developing a PGC could not be clarified in this study; this effect was only modified in afro descendant ethnicity where HTN decreased the odds of a PGC. Further studies evaluating the effect that pharmacological and lifestyle interventions could have in the association of interest are needed.

**Abbreviations**

ASD: Absolute Standard Differences, BMI: Body Mass Index, CKD: Chronic Kidney Disease, CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration, DM: Diabetes Mellitus, GFR: Glomerular Filtration Rate, HbA1c: Hemoglobin A1c, HTN: hypertension, IQR: Interquartile range, NRCKD: National Registry of Chronic Kidney Disease, PGC: Poor Glycemic Control SD: Standard deviation

**Declarations**

**Ethics declaration**

Approval by the Ethics Committee of Fundación del Caribe para la Investigación Biomédica (Record 0211 from October 17th, 2020) was obtained. According to the national regulations for conducting human research (Resolution 8430 of 1993, stated by The Colombian Health Ministry), this investigation has no risk for participants. Our research was based on secondary data sources which was anonymized and did not include any private information that could make any subject identifiable. Taking into account the above, informed consent was not required.

**Consent for publication**

Not applicable

**Availability of data and materials**

The datasets generated and/or analysed during the current study are not publicly available due to that they are owned by the Colombian health system but are available from the corresponding author on reasonable request.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

This research did not receive any sources of funding.

**Authors’ contributions**

MUJ, LJHP, JAHV, AMVG, LAM, MUT were involved in the conception and design of the study. LJHP and JAHV conducted the statistical analyses and tables/figures. AMVG supervised the statistical analyses. MUJ, LJHP, JAHV, AMVG, LAM, MUT contributed to the interpretation of the analyses. MUJ and JAHV wrote the initial draft of
the paper. MUJ, LJHP, JAHV, AMVG, LAM, MUT contributed to the revision of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We would like to thank Dr. Oscar Leonel Rueda and Dr. Lyda Rojas for their recommendations and comments on the manuscript.

References

1. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157.
2. Vargas-Uricoechea H, Casas-Figueroa LÁ. An Epidemiologic Analysis of Diabetes in Colombia. Annals of Global Health. 2015;81:742–53.
3. Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW. Global trends in diabetes complications: a review of current evidence. Diabetologia. 2019;62:3–16.
4. Herman WH, Braffett BH, Kuo S, Lee JM, Brandle M, Jacobson AM, et al. What are the clinical, quality-of-life, and cost consequences of 30 years of excellent vs. poor glycemic control in type 1 diabetes? J Diabetes Complications. 2018;32:911–5. doi:10.1016/j.jdiacomp.2018.05.007.
5. Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5:431–7. doi:10.1016/S2213-8587(17)30104-3.
6. Ray KK, Seshasai SRK, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373:1765–72. doi:10.1016/S0140-6736(09)60697-8.
7. Hayward RA, Reaven PD, Wiitala WL, Bahn GD, Reda DJ, Ge L, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;372:2197–206.
8. Mannucci E, Monami M, Dicembrini I, Piselli A, Porta M. Achieving HbA1c targets in clinical trials and in the real world: A systematic review and meta-analysis. J Endocrinol Invest. 2014;37:477–95.
9. De Pablos-Velasco P, Parhofer KG, Bradley C, Eschwège E, Gönder-Frederick L, Maheux P, et al. Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: Data from the PANORAMA study. Clin Endocrinol (Oxf). 2014;80:47–56.
10. Smalls BL, Ritchwood TD, Bishu KG, Egede LE. Racial/Ethnic Differences in Glycemic Control in Older Adults with Type 2 Diabetes: United States 2003-2014. International journal of environmental research and public health. 2020;17.
11. Suh DC, Choi IS, Plauschinat C, Kwon J, Baron M. Impact of comorbid conditions and race/ethnicity on glycemic control among the US population with type 2 diabetes, 1988-1994 to 1999-2004. J Diabetes Complications. 2010;24:382–91. doi:10.1016/j.jdiacomp.2009.07.001.
12. Chetoui A, Kaoutar K, Elmoussaoui S, Boutahar K, El Kardoudi A, Chigr F, et al. Prevalence and determinants of poor glycaemic control: a cross-sectional study among Moroccan type 2 diabetes patients. Int Health.
Iglay K, Hannachi H, Howie PJ, Xu J, Li X, Engel SS, et al. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. Curr Med Res Opin. 2016;32:1243–52.

Luijks H, Biermans M, Bor H, Van Weel C, Lagro-Janssen T, De Grauw W, et al. The effect of comorbidity on glycemic control and systolic blood pressure in type 2 diabetes: A cohort study with 5 year follow-up in primary care. PLoS One. 2015;10.

Bralić Lang V, Bergman Marković B. Prevalence of comorbidity in primary care patients with type 2 diabetes and its association with elevated HbA1c: A cross-sectional study in Croatia. Scand J Prim Health Care. 2016;34:66–72.

Hudon C. Comorbidity and glycemia control among patients with type 2 diabetes in primary care. Diabetes, Metab Syndr Obes Targets Ther. 2008;Volume 1:33–7.

Almetwazi M, Alwhaibi M, Balkhi B, Almohaini H, Alturki H, Alhawassi T, et al. Factors associated with glycemic control in type 2 diabetic patients in Saudi Arabia. Saudi Pharm J. 2019;27:384–8.

Alzaheb RA, Altemani AH. The prevalence and determinants of poor glycemic control among adults with type 2 diabetes mellitus in Saudi Arabia. Diabetes, Metab Syndr Obes Targets Ther. 2018;11–5. doi:10.2147/DMSO.S156214.

Ministerio de Salud y Proteccion Social - Republica de Colombia. Resolucion 2643 del 2014. 2014;1–13. https://cuentadealtocosto.org/site/wp-content/uploads/2019/10/Resolucion-02463-de-2014-ERC.pdf. Accessed 9 Oct 2020.

Ministerio de Salud y Proteccion Social - Republica de Colombia. Cifras de aseguramiento en salud con corte diciembre 2020. 2020. https://www.minsalud.gov.co/proteccionsocial/Paginas/cifras-aseguramiento-salud.aspx. Accessed 19 Jan 2021.

World Health Organization. Obesity: Preventing and managing the global epidemic. Report of a WHO Consultation (WHO Technical Report Series 894). Geneva, Switzerland; 2000. https://www.who.int/nutrition/publications/obesity/WHO_TRS_894/en/.

Levey AS, Stevens LA, Schmid CH, Zhang Y (Lucy), Castro AF, Feldman HL, et al. A New Equation to Estimate Glomerular Filtration Rate. Ann Intern Med. 2009;150:604. doi:10.7326/0003-4819-150-9-200905050-00006.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3:1–150. https://kdigo.org/guidelines/ckd-evaluation-and-management/.

Yang D, Dalton J. A unified approach to measuring the effect size between two groups using SAS®. SAS Glob Forum. 2012; 6.

Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020;98:S1–115.
28. De Cosmo S, Viazzi F, Pacilli A, Giorda C, Ceriello A, Gentile S, et al. Achievement of therapeutic targets in patients with diabetes and chronic kidney disease: Insights from the Associazione Medici Diabetologi Annals initiative. Nephrol Dial Transplant. 2015;30:1526–33.

29. Bae JP, Lage MJ, Mo D, Nelson DR, Hoogwerf BJ. Obesity and glycemic control in patients with diabetes mellitus: Analysis of physician electronic health records in the US from 2009-2011. J Diabetes Complications. 2016;30:212–20.

30. Speeckaert M, Van Biesen W, Delanghe J, Slingerland R, Wiecek A, Heaf J, et al. Are there better alternatives than haemoglobin A1c to estimate glycaemic control in the chronic kidney disease population? Nephrol Dial Transplant. 2014;29:2167–77.

31. Hill CJ, Maxwell AP, Cardwell CR, Freedman BI, Tonelli M, Emoto M, et al. Glycated hemoglobin and risk of death in diabetic patients treated with hemodialysis: A meta-analysis. Am J Kidney Dis. 2014;63:84–94.

32. Kuo IC, Lin HYH, Niu SW, Hwang DY, Lee JJ, Tsai JC, et al. Glycated Hemoglobin and Outcomes in Patients with Advanced Diabetic Chronic Kidney Disease. Sci Rep. 2016;6 January:1–9. doi:10.1038/srep20028.

33. Esteghamati A, Ismail-Beigi F, Khaloo P, Moosaie F, Alemi H, Mansournia MA, et al. Determinants of glycemic control: Phase 2 analysis from nationwide diabetes report of National Program for Prevention and Control of Diabetes (NPPCD-2018). Prim Care Diabetes. 2020;14:222–31. doi:10.1016/j.pcd.2019.07.002.

34. Gummesson A, Nyman E, Knutsson M, Karpefors M. Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type 2 diabetes. Diabetes, Obes Metab. 2017;19:1295–305.

35. Badedi M, Solan Y, Darraj H, Sabai A, Mahfouz M, Alamodi S, et al. Factors Associated with Long-Term Control of Type 2 Diabetes Mellitus. J Diabetes Res. 2016;2016.

Table

Due to technical limitations, table 1 docx is only available as a download in the Supplemental Files section.